CTKB logo

CYTEK BIOSCIENCES INC

CTKBNASDAQ
πŸ† #2526 by market capEarnings Nov 4 Β· PostUS Equity
$6.30β–² $0.17 (+2.77%)
Pre-market Β· at close
πŸ””
Track CTKB
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.8%
7dβ–² 12.9%
14dβ–² 19.8%
30dβ–² 5.7%
ytdβ–² 24.9%
1yβ–² 64.9%
🏦Market Cap
$819M
Small Cap
πŸ“ˆRevenue Growth (YoY)
5.4%
Slowing
πŸ“ŠGross Margin
53.2%
Healthy
πŸ’΅FCF Margin
10.5%
Healthy
βš–οΈP/S Ratio
4.0x
Fair
Otter Score
72
Strong

Trading Snapshot

Day Range
$6.04 – $6.33
52-Week Range
$3.31 – $6.32
Volume (shares)
148,392
Avg Volume (shares)
β€”
Shares Outstanding
130.0M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$201M
Last Q Revenue
$48M
P/E Ratio
β€”
P/S Ratio
4.0x
EPS (TTM)
$-0.63
Dividend Yield
β€”
Dilution (1yr)
βˆ’0.8%
CTKB logo

CYTEK BIOSCIENCES INC

CTKB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$201Mβ–² +0.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.8%β–Ό βˆ’6.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$40Mβ–² +96.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$9Mβ–Ό βˆ’140.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
128.2Mβ–Ό βˆ’0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$67Mβ–Ό βˆ’$15M YoY
StockOtter Β· stockotter.space

About CYTEK BIOSCIENCES INC

Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100

Analyst Ratings

β“˜
Consensus
Buy
10 analysts
Strong Buy3
Buy4
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.